In particular this comment from new CEO. Bit of a plug ans a hint ?
We are delighted to receive this award and I would like to thank our tremendous team who embody the spirit of innovation. At Fusion we are continuously innovating to enhance our capability to deliver services and solutions that allow our clients to develop the best possible antibodies against their target getting them closer to their end goal; the provision of treatments that improve the lives of patients throughout the world.
“Unlike many of our competition, our library design approach explores the natural hypermutation space; in essence, we believe that when it comes to engineering antibodies, the sequence should be kept as natural as possible and so ‘mimics’ the human system.
“I am immensely proud of what everyone has worked so hard together to achieve. It’s a great way to start 2021 which promises to be another exciting year for the company, with a number of new exciting developments already in the pipeline.”
Fusion Antibodies is delighted to be recognised as a Platinum Level Innovator in the Innovate NI Innovation Accreditation programme from the Department for the Economy.
The scheme recognises businesses across Northern Ireland who have shown innovation in their processes, products and or services. The platinum level indicates Fusion Antibodies have secured commercial benefits from their innovation. Fusion Antibodies have received this certification for their innovative antibody engineering and discovery platforms which have been developed based on their own intelligent design.
The Programme aims to highlight the importance of innovation for business growth, create more awareness of the value of innovation, as well as how to innovate. The ultimate goal is to increase the number of Northern Ireland businesses successfully engaging in innovation activity.
On receiving the award Dr Richard Jones, CEO of Fusion Antibodies, said:
“We are delighted to receive this award and I would like to thank our tremendous team who embody the spirit of innovation. At Fusion we are continuously innovating to enhance our capability to deliver services and solutions that allow our clients to develop the best possible antibodies against their target getting them closer to their end goal; the provision of treatments that improve the lives of patients throughout the world.
“Unlike many of our competition, our library design approach explores the natural hypermutation space; in essence, we believe that when it comes to engineering antibodies, the sequence should be kept as natural as possible and so ‘mimics’ the human system.
“I am immensely proud of what everyone has worked so hard together to achieve. It’s a great way to start 2021 which promises to be another exciting year for the company, with a number of new exciting developments already in the pipeline.”
Economy Minister Diane Dodds said:
“The Innovation Accreditation Programme supports businesses to invest in innovation and improve their competitiveness. The scheme emphasises the value of innovation for business growth. Innovation is so important at this difficult time because it is essential to economic recovery. I want to congratulation Fusion Antibodies on this award and on their work on in advancing the life sciences sector.”
Congratulating the company, Dr Vicky Kell, Invest NI’s Director of Innovation, Research & Development said:
“Fusion Antibodies is a highly innovative company which has benefitted from Invest NI support for R&D to position itself as a world leader in antibody development.
“It has never been more critical to support innovation within the life sciences industry and Fusion Antibodies is an excellent example of an organisation recognising the importance of investing in R&D to maintain a competitive business beyond COVID-19.
“It is great to see the company’s hard work, effort and determination being recognised through the Innovation Accreditation Programme.
https://t.co/kGm2eBqAcJ?amp=1
Why don’t they tell the shareholders.
Well as soon as this overhang is cleared it looks like the volume will continue and I would imagine new highs will be challenged.
The buying is relentless. So it must be a very very large sell order being worked. Has to be placing shares.
I guess that depends if the seller of placing shares creates a panic sell off or stops and is cleared by the clear volume of buyers that are mopping up stock. My guess is MM want to create a panic sell off
They know spread bets who got in long before the change can’t reload lower down as no new positions can be added. Well at IG that’s the case.
Well there is still clearly a big overhang of a very large sell order providing all these shares being purchased. Follow on feom yesterday.
Must still be a lot of placing shares to be flipped.
Crashing in Aus 20% down think this will gap down in the morning ? Couldn’t sell all afternoon today couldn’t exit any of spread bet position. Expect those big sells were massive sells did you not all see they were feom 15/2 yesterday. Not today. !!!
Clearly placing money being cashed in for huge profits. Any buyers in last two days will be spiked as this tracks back down after the hype.
Will be some time before this gets back above 4p
Bobat please explain to me how Market makers can be collecting shares if Buys are being shown as sellls. Surely that implies the MM are getting shorter and shorter and shorter. So it is far more likely they are working a huge sell order.
It was just catching up with LSE at 1.78 Aus to Sterling 7.78 = 4.35.
So we have equilibrium
Not the news we were expecting. I houses initial reaction will be bad as market never likes change of CEO but looks to me like the new CEO has much more experience to take a project forward ans build a business.
That’s what we need as they grow the Optimal monoclonal antibody library.
So we shall see how the market reacts
Huge huge delayed volume from Fridays trading
Anyone who wanted to off load the placing shares must have surely done that by now.
So shares being churned and more will be going to long term homes I believe.
Looks great long term prospect to me.
IG no longer allowing new spread bet open positions. Brokers must be well short of stock the margins been increased hence the close only stance.
I recommend all new to this share listen to the Q&A on Meet the company website. After the presentation on 23/11. You will really get an insight to the valuations the company anticipate.
First decent blue day in quite a while. And not really on huge volume just shows what will happen to this share when they actually produce some good news on the Optimal Antibody library.
That should happen with the Covid Antibody project news. Could land any day it could already be with the University of Belfast to verify. Who knows.
I have had this plantation to my enquiry about the Omega testing and they statemen in our antigen RNS back in Sueptember
Hi Paul,
He was saying pretty much what I said.
The first part of his statement of ‘Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19’ is talking about testing for antibodies raised in the body due to infections with Covid (i.e past infections) and not testing for Covid itself. He also was pointing out that this type of test could also be used to test for testing for levels of therapeutic neutralising antibodies administered to the patient.
The Omega test that was in today’s announcement is not for antibodies raised due to an infection but for the actual Covid virus itself.
Regards
Simon
ODX wins contract to supply up to 2 million antigen flow tests to government
So Who provides the antigens could it be Fusion Antibodies seeing as the new Chairman just also appointed by ODX is also Chairman of FAB ?
Anyone any idea ?
I?m a big fan of FAB so be nice to know.